Private investment in healthcare is increasingly criticized for prioritizing high-margin, premium markets over the systemic needs of global health, according to Mathieu Morand, Director of the C/Can Accelerator Hub at City Cancer Challenge. During the World Cancer Series, industry observers highlighted a fundamental misalignment between traditional venture capital (VC) return-on-investment timelines and the long-term infrastructure required to solve global access gaps in cancer care.
Why Is Private Capital Misaligned With Public Health Needs?
The primary friction point is the standard investment horizon, which typically demands returns within an eight-year window. According to Morand, this timeline forces venture capital and private equity firms to focus on affluent, well-insured population segments where profitability is rapid. Because these models prioritize premium markets, they frequently overlook the “access gaps” that define the public health systems in low- and middle-income countries. While the deals are financially sound for the investors, they fail to address the systemic innovation requirements of global health agencies.
The typical venture capital fund lifecycle is roughly 10 years, with the most intense focus on liquidity events (like exits or IPOs) occurring between years five and eight. This urgency often precludes investments in long-term public health infrastructure, which may take decades to mature.
How Can Incentives Be Realigned to Prioritize Access?
Industry leaders are calling for a shift in success metrics to move beyond simple financial returns. Morand suggests that the current model, which relies on the goodwill of entrepreneurs or the limited budgets of NGOs, is insufficient to meet the pace of medical innovation. Potential solutions include:
- Regulatory Interventions: Implementing policy requirements that mandate access strategies as a condition for market approval or tax incentives.
- Blended Finance Models: Combining philanthropic capital with private equity to de-risk investments in underserved regions.
- Outcome-Based Metrics: Redefining “success” for healthcare startups to include patient reach and health outcomes in addition to EBITDA.
Who Should Drive Sustainable Healthcare Innovation?
The responsibility for equitable access remains a point of contention among stakeholders. While private investors argue their job is to generate returns, public health advocates like Morand question whether international agencies or government regulators must step in to bridge the gap. As innovation cycles accelerate, the “buy-out” culture—where large pharmaceutical firms acquire smaller, innovative companies—often results in the consolidation of technology rather than its democratization. Without a structural change, these innovations remain inaccessible to the majority of the global population.
Pro Tip: The Role of Public-Private Partnerships (PPP)
To improve access, look for partnerships that explicitly define “access” as a key performance indicator (KPI) from the project’s inception. Successful models often involve a government entity guaranteeing a baseline volume of service, which reduces the financial risk for the private investor.
Frequently Asked Questions
- Why don’t private investors focus more on global health access?
- The structural constraints of VC funds require high, short-term returns. Global health initiatives often involve complex distribution logistics and lower per-patient revenue, which do not align with the standard 8-year exit strategy.
- What is the “C/Can Accelerator Hub”?
- The City Cancer Challenge (C/Can) Accelerator Hub works to support cities in improving access to equitable, quality cancer care by connecting local health systems with global technical and financial resources.
- Can innovation be embedded into a business model from the start?
- Yes, through “inclusive innovation” or “frugal innovation” strategies, where companies design products specifically for resource-constrained environments, ensuring lower costs and higher accessibility without sacrificing efficacy.
Are you working at the intersection of public health and private investment? Join the conversation by sharing your experiences in the comments below or subscribe to our newsletter for more insights into the future of global cancer care.
